Page 2 - மருந்து பாதுகாப்பு புதுப்பிப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana
COVID-19 vaccines: updates for July 2021
gov.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gov.uk Daily Mail and Mail on Sunday newspapers.
Oral retinoid medicines (isotretinoin▼, alitretinoin▼, and acitretin▼): temporary monitoring advice during coronavirus (COVID-19) pandemic
gov.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gov.uk Daily Mail and Mail on Sunday newspapers.
Chloramphenicol eye drops containing borax or boric acid buffers: use in children younger than 2 years
gov.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gov.uk Daily Mail and Mail on Sunday newspapers.
Advice for healthcare professionals:
counsel women of childbearing potential about the possible risk of neural tube defects with dolutegravir, including consideration of effective contraceptive measures
discuss the benefits and the risks of continuing treatment with dolutegravir to women who are trying to become pregnant
if a pregnancy is confirmed in the first trimester while a patient is on dolutegravir, the benefits and risks of continuing dolutegravir versus switching to another antiretroviral regimen should be discussed with the patient, taking into account the gestational age and the critical time period of neural tube defect development
report any suspected adverse drug reactions associated with dolutegravir to the Yellow Card scheme
Here we include a summary of key MHRA advice issued since the publication of the January 2021 edition of Drug Safety Update and up to 16 February 2021.
Yellow Card reporting data confirms safety of vaccines
The data confirms that the vast majority of reported side effects are mild and short-lasting, reflecting a normal immune response to vaccines – including a sore arm and fatigue.
The report summarises information received via the Yellow Card scheme and will be published regularly to include other safety investigations carried out by the MHRA under the COVID-19 Vaccine Surveillance Strategy.
We take every report of a suspected adverse reaction seriously and encourage everyone to report through the Coronavirus Yellow Card reporting site.